Targeting Galectin-3 has been suggested as treatment for COVID-19 not only due to its role in fibrosis and systemic inflammation, but also due to its potential involvement in the virus-host interaction mediated by the N-terminal domain of SARS-CoV-235,36. Here, LGALS3 is linked to COVID-19.